These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27899263)

  • 61. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
    Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
    J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Hyams JS; Dubinsky M; Rosh J; Ruemmele FM; Eichner SF; Maa JF; Lazar A; Alperovich G; Mostafa NM; Robinson AM
    Aliment Pharmacol Ther; 2019 Jan; 49(2):155-164. PubMed ID: 30506693
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
    Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
    D'Haens GR; Sandborn WJ; Loftus EV; Hanauer SB; Schreiber S; Peyrin-Biroulet L; Panaccione R; Panés J; Baert F; Colombel JF; Ferrante M; Louis E; Armuzzi A; Zhou Q; Goteti VS; Mostafa NM; Doan TT; Petersson J; Finney-Hayward T; Song AP; Robinson AM; Danese S
    Gastroenterology; 2022 Jun; 162(7):1876-1890. PubMed ID: 35122766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic strategy for Crohn's disease with a loss of response to infliximab: a single-center retrospective study.
    Nagata Y; Esaki M; Umeno J; Fuyuno Y; Ikegami K; Maehata Y; Asano K; Moriyama T; Nakamura S; Kitazono T; Matsumoto T
    Digestion; 2015; 91(1):50-6. PubMed ID: 25632918
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme M; Sharma A; Keld R; Willert R; Campbell S
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intensification of infliximab therapy in Crohn's disease: efficacy and safety.
    M Chaparro ; Martínez-Montiel P; Van Domselaar M; Bermejo F; Pérez-Calle JL; Casis B; Román AL; Algaba A; Maté J; Gisbert JP
    J Crohns Colitis; 2012 Feb; 6(1):62-7. PubMed ID: 22261529
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States.
    Loftus EV; Pan X; Zurawski P; Mulani P; Chao J
    J Crohns Colitis; 2011 Dec; 5(6):550-4. PubMed ID: 22115373
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study).
    Asada T; Nakayama G; Tanaka C; Kobayashi D; Ezaka K; Hattori N; Kanda M; Yamada S; Koike M; Kodera Y
    Surg Today; 2018 Jun; 48(6):609-617. PubMed ID: 29476258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
    Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
    Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.